Application No.: 10/511,612 Docket No.: CNZ-006USRCE

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in this application.

1. (Currently Amended) A method of treating an inflammatory disorder in a patient <u>in</u> need thereof, wherein the method comprises comprising, the method comprising

administering to said patient a pharmaceutical composition comprising a pharmaceutically acceptable carrier, wherein said composition comprises and at least one agent selected from the group consisting of: heme oxygenase-1 (HO-1), bilirubin, biliverdin, ferritin, iron, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, or apoferritin, and an agent that induces endogenous HO-1 in the subject, wherein the composition is administered in an amount sufficient to treat the inflammatory disorder; and wherein the inflammatory disorder is localized in the gastrointestinal tract.

- 2. (**Currently Amended**) The method of claim 1, wherein the <u>composition comprises</u> treatment is inducing ferritin in the patient.
 - 3. (Cancelled)
- 4. (Currently Amended) The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprises an agent that induces endogenous comprising HO-1 to in the patient.
- 5. (Currently Amended) The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising comprises biliverdin to the patient.
- 6. (Currently Amended) The method of claim 5, wherein the pharmaceutical composition biliverdin is administered to the patient at a dosage of about 1 to 1000 micromoles/kg/day.

Application No.: 10/511,612 Docket No.: CNZ-006USRCE

7. (**Previously Presented**) The method of claim 1, wherein the inflammatory disorder is ulcerative colitis.

- 8. (**Currently Amended**) The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising comprises bilirubin to the patient.
- 9. (Currently Amended) The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising comprises ferritin to the patient.
- 10. (Currently Amended) The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising comprises at least one of desferoxamine (DFO) or salicylaldehyde isonicotinoyl hydrazone (SIH) to the patient.
- 11. (Currently Amended) The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising comprises iron dextran to the patient.
- 12. (Currently Amended) The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising comprises apoferritin to the patient.
- 13. (Currently Amended) The method of claim 2, wherein the ferritin is induced by administering composition comprises iron to the patient.

14-16. (**Cancelled**)

17. (**Previously Presented**) The method of claim 1, wherein the inflammatory disorder is selected from the group consisting of: amoebic dysentery, bacillary dysentery, schistosomiasis, campylobacter enterocolitis, yersinia enterocolitis, enterobius vermicularis, radiation enterocolitis, ischaemic colitis, eosinophilic gastroenteritis, ulcerative colitis, indeterminate colitis, and Crohn's disease.

Application No.: 10/511,612 Docket No.: CNZ-006USRCE

18. (**Previously Presented**) The method of claim 1, wherein the inflammatory disorder is ulcerative colitis.

19. (Cancelled)

20. (**Currently Amended**) The method of claim 1, further comprising the <u>step of steps</u> of inducing HO 1 in the patient, and administering a pharmaceutical composition comprising carbon monoxide to the patient.

21-62. (**Cancelled**)

- 63. (New) The method of claim 1, wherein the composition comprises at least two of the agents.
- 64. (New) The method of claim 63, wherein the composition comprises biliverdin and an agent that induces endogenous HO-1.
- 65. (New) The method of claim 63, wherein the composition comprises bilirubin and an agent that induces endogenous HO-1.
 - 66. (New) The method of claim 1, wherein the at least one agent is administered orally.